Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Thomason

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
The Pediatric Infectious Disease Journal|July 29, 2014
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyMutsawashe Bwakura-Dangarembizi, Victor Musiime, Alexander J Szubert, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 15, 2020
Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trialD T Wademan, L Busakwe, T J Nicholson, et al.
Antimicrobial Resistance and Infection Control|August 30, 2020
Antimicrobial resistance preparedness in sub-Saharan African countriesLinzy Elton, Margaret J Thomason, John Tembo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY TrialAbraham Siika, Leanne McCabe, Mutsa Bwakura-Dangarembizi, et al.
Plos Medicine|November 15, 2017
Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trialAlexander J Szubert, Andrew J Prendergast, Moira J Spyer, et al.
The Lancet. Infectious Diseases|November 8, 2017
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialJames G Hakim, Jennifer Thompson, Cissy Kityo, et al.
AIDS (London, England)|April 12, 2016
Once vs twice-daily abacavir and lamivudine in African childrenVictor Musiime, Philip Kasirye, Bethany Naidoo-James, et al.
Critical Care (London, England)|November 29, 2019
Mortality risk over time after early fluid resuscitation in African childrenElizabeth C George, Sarah Kiguli, Peter Olupot Olupot, et al.
Trials|December 22, 2018
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)James A Seddon, Anthony J Garcia-Prats, Susan E Purchase, et al.
The Lancet. Infectious Diseases|October 21, 2015
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trialVeronica Mulenga, Victor Musiime, Adeodata Kekitiinwa, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
The Pediatric Infectious Disease Journal|July 29, 2014
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyMutsawashe Bwakura-Dangarembizi, Victor Musiime, Alexander J Szubert, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 15, 2020
Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trialD T Wademan, L Busakwe, T J Nicholson, et al.
Antimicrobial Resistance and Infection Control|August 30, 2020
Antimicrobial resistance preparedness in sub-Saharan African countriesLinzy Elton, Margaret J Thomason, John Tembo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2018
Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY TrialAbraham Siika, Leanne McCabe, Mutsa Bwakura-Dangarembizi, et al.
Plos Medicine|November 15, 2017
Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trialAlexander J Szubert, Andrew J Prendergast, Moira J Spyer, et al.
The Lancet. Infectious Diseases|November 8, 2017
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialJames G Hakim, Jennifer Thompson, Cissy Kityo, et al.
AIDS (London, England)|April 12, 2016
Once vs twice-daily abacavir and lamivudine in African childrenVictor Musiime, Philip Kasirye, Bethany Naidoo-James, et al.
Critical Care (London, England)|November 29, 2019
Mortality risk over time after early fluid resuscitation in African childrenElizabeth C George, Sarah Kiguli, Peter Olupot Olupot, et al.
Trials|December 22, 2018
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)James A Seddon, Anthony J Garcia-Prats, Susan E Purchase, et al.
The Lancet. Infectious Diseases|October 21, 2015
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trialVeronica Mulenga, Victor Musiime, Adeodata Kekitiinwa, et al.
Pageof 16